NASDAQ:ZSAN - Zosano Pharma Stock Price, News & Analysis

$2.76
-0.01 (-0.36 %)
(As of 08/19/2019 04:00 PM ET)
Today's Range
$2.6009
Now: $2.76
$2.80
50-Day Range
$2.61
MA: $3.03
$3.50
52-Week Range
$1.85
Now: $2.76
$6.65
Volume205,857 shs
Average Volume1.10 million shs
Market Capitalization$48.92 million
P/E RatioN/A
Dividend YieldN/A
Beta2.6
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.07 per share

Profitability

Net Income$-35,360,000.00

Miscellaneous

Employees53
Market Cap$48.92 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter.


Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Shares of Zosano Pharma reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Corp (NASDAQ:ZSAN) announced its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.56) by $0.01. View Zosano Pharma's Earnings History.

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Zosano Pharma.

What price target have analysts set for ZSAN?

3 equities research analysts have issued 12 month price targets for Zosano Pharma's shares. Their predictions range from $3.66 to $19.00. On average, they expect Zosano Pharma's stock price to reach $10.22 in the next twelve months. This suggests a possible upside of 270.3% from the stock's current price. View Analyst Price Targets for Zosano Pharma.

What is the consensus analysts' recommendation for Zosano Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.

Has Zosano Pharma been receiving favorable news coverage?

News articles about ZSAN stock have been trending negative on Monday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Zosano Pharma earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Zosano Pharma.

Are investors shorting Zosano Pharma?

Zosano Pharma saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 1,360,000 shares, a decrease of 5.9% from the June 30th total of 1,444,600 shares. Based on an average trading volume of 289,000 shares, the short-interest ratio is presently 4.7 days. Currently, 14.5% of the shares of the company are sold short. View Zosano Pharma's Current Options Chain.

Who are some of Zosano Pharma's key competitors?

What other stocks do shareholders of Zosano Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Synergy Pharmaceuticals (SGYP), AEterna Zentaris (AEZS), Square (SQ), Anthera Pharmaceuticals (ANTH), Immunomedics (IMMU), Protalix Biotherapeutics (PLX), Evoke Pharma (EVOK), Iovance Biotherapeutics (IOVA), Neovasc (NVCN) and Verastem (VSTM).

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the folowing people:
  • Mr. John P. Walker, Chairman, CEO & Pres (Age 70)
  • Ms. Hayley Lewis, Sr. VP of Operations (Age 43)
  • Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 64)
  • Mr. Greg Kitchener, Chief Financial Officer (Age 48)
  • Jeffrey L. Quillen, Sec.

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Who are Zosano Pharma's major shareholders?

Zosano Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Aisling Capital Management LP (90.29%), Vanguard Group Inc. (5.40%), BlackRock Inc. (2.07%), Wedbush Securities Inc. (0.12%) and Jane Street Group LLC (0.06%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc, John Peter Walker and Kenneth Greathouse. View Institutional Ownership Trends for Zosano Pharma.

Which institutional investors are buying Zosano Pharma stock?

ZSAN stock was bought by a variety of institutional investors in the last quarter, including Aisling Capital Management LP, Vanguard Group Inc., BlackRock Inc., Wedbush Securities Inc. and Jane Street Group LLC. Company insiders that have bought Zosano Pharma stock in the last two years include John Peter Walker and Kenneth Greathouse. View Insider Buying and Selling for Zosano Pharma.

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $2.76.

How big of a company is Zosano Pharma?

Zosano Pharma has a market capitalization of $48.92 million. The biotechnology company earns $-35,360,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.View Additional Information About Zosano Pharma.

What is Zosano Pharma's official website?

The official website for Zosano Pharma is http://www.zosanopharma.com/.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]


MarketBeat Community Rating for Zosano Pharma (NASDAQ ZSAN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote "Outperform" if you believe ZSAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZSAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Featured Article: What is the Rule of 72?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel